Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Articles: DFG German National Licenses  (2)
  • Carbamazepin  (1)
  • Dopamine agonists  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 64 (1986), S. 314-318 
    ISSN: 1432-1440
    Keywords: Hypothalamus ; Anterior pituitary ; Releasing hormones ; Dopamine agonists
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Anterior pituitary function was investigated in ten healthy subjects by administering a combination of 200 µg thyrotropin releasing hormone (TRH), 100 µg gonadotropin releasing hormone (GnRH), 100 µg growth hormone releasing factor (GRF1–44), and 100 µg human corticotropin releasing factor (CRF). The same test protocol was performed in all subjects after pretreatment with 0.25 mg terguride. Five subjects were tested only with TRH and GnRH, five only with CRF, and six only with GRF. There was a prompt increase in all hormones after the administration of the four releasing hormones (RH). Pretreatment with terguride lowered the prolactin (PRL) increase (p〈0.01) as well as the thyrotropin (TSH) peak (p〈0.05) compared with the test without dopamine agonist pretreatment. The PRL levels after combined RH administration were significantly higher than after TRH and GnRH alone. Although four of the five subjects had higher TSH levels after combined RH administration than after TRH and GnRH alone, the difference was not significant. Other hormones were not significantly influenced by the combined RH administration or dopamine agonist pretreatment. Despite the fact that the interaction of the different releasing hormones and dopamine agonists influences the pituitary hormone response, combined RH administration seems to be a useful test for evaluating pituitary function also in patients receiving dopamine agonist therapy.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 50 (1972), S. 981-983 
    ISSN: 1432-1440
    Keywords: Carbamazepine ; Growth Hormone ; Carbamazepin ; Wachstumshormon
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Die Bedeutung einer medikamentösen Therapie der Akromegalie veranlaßte uns, eine aufgrund klinischer Befunde geäußerte Vermutung eines therapeutischen Effektes von Carbamazepin bei der Akromegalie zu überprüfen. Dazu wurde der Einfluß von Carbamazepin auf die Arginin, stimulierte Wachstumshormonsekretion bei 10 endokrin Gesunden und 3 Patienten mit einer Akromegalie untersucht. Bei den endokrin Gesunden war der Arginin-induzierte Anstieg der GH-Spiegel nach 5tägiger Applikation von 3·200 mg/die Carbamazepin nicht signifikant verschieden von dem GH-Anstieg vor Carbamazepingabe. Bei 2 Patienten mit erfolgreich operierter und bei einer Patientin mit florider Akromegalie führte Carbamazepin ebenfalls weder zu einer Suppression der GH-Nüchternspiegel noch zur Hemmung der GH-Sekretion nach Arginin. Die Befunde zeigen, daß Carbamazepin im Gegensatz zu der von anderen Autoren geäußerten Vermutung für eine medikamentöse Therapie der Akromegalie nicht geeignet ist. Wenn Carbamazepin wegen seines antikonvulsiven oder antidiuretischen Effektes im Kindesalter eingesetzt werden soll, bestehen hinsichtlich einer Wachstumshemmung infolge von GH-Mangel keine Bedenken.
    Notes: Summary On account of purely clinical observations it has been suggested that carbamazepine might be of value in the treatment of acromegaly. To determine the possible role of carbamazepine in the treatment of this disease, the influence of carbamazepine on arginine induced growth hormone secretion was investigated in 10 patients without endocrine diseases and in 3 acromegalics. The increase in serum GH provoked by arginine in 10 patients without endocrine diseases after 5 days of carbamazepine application (3·200 mg/day) was not significantly different from the GH-increase before carbamazepine. In two patients after hypophysectomy and in one patient with floride acromegaly no effect of carbamazepine on arginine induced GH-secretion and on basal GH levels was seen. According to these findings carbamazepine is not a drug suited for the medical management of acromegaly as has been suggested before. It may therefore be used in growing children, if anticonvulsive or antidiuretic therapy is indicated since an effect on growth hormone secretion could not be detected.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...